ALSO NOTED: Sepracor touts Lunesta trial; SkyePharma outlines gains; ArQule highlights cancer results; and much more...

> Sepracor announced that a new study of Lunesta demonstrated that it improved the sleep of premenopausal and menopausal women suffering from insomnia. Lunesta was approved by the FDA last December for people who have trouble sleeping through the night. Report

> SkyePharma's drug development partner First Horizon has released the heart drug Trigline in the US market, the first of eight strategic gains marked by the London-based developer at its annual meeting. Release

> ArQule is touting preclinical data showing that activating Chk2 in the absence of chemotherapy kills cancer cells. Report

> Xencor has inked a new collaboration deal to develop monoclonal antibodies with improved efficacy -- this time with Centocor. Release

> The FDA approved an implantable device developed by Cyberonics for treating depression. Story

> Bayer HealthCare's Avelox IV has been approved in Europe to treat complicated skin infections. Release

And Finally... The absence of generic competition is helping to keep the cost of biotech drugs high. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.